The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo

Lannoy, M.; Valluru, M.K.; Chang, L.J.; Abdela-Ali, F.; Peters, D.J.M.; Streets, A.J.; Ong, A.C.M.

Citation

Version: Publisher's Version
License: Creative Commons CC BY 4.0 license
Downloaded from: https://hdl.handle.net/1887/3184595

Note: To cite this publication please use the final published version (if applicable).
The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis *in vitro* is counteracted by increased kidney inflammation *in vivo*

Morgane Lannoy1,2, Manoj K. Valluru1,2, Lijun Chang1,2, Fatima Abdela-Ali1,2, Dorien J.M. Peters3, Andrew J. Streets1,2 and Albert C.M. Ong1,2

1Kidney Genetics Group, Academic Nephrology Unit, University of Sheffield Medical School, Sheffield, UK; 2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK; and 3Department of Human Genetics, Leiden University Medical Center (LUMC), Leiden, The Netherlands

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a major cause of end-stage kidney disease in man. The central role of cyclic adenosine monophosphate (cAMP) in ADPKD pathogenesis has been confirmed by numerous studies including positive clinical trial data. Here, we investigated the potential role of another major regulator of renal cAMP, prostaglandin E2 (PGE2), in modifying disease progression in ADPKD models using selective receptor modulators to all four PGE2 receptor subtypes (EP1-4). In 3D-culture model systems ADPKD models using selective receptor modulators to all four PGE2 receptor subtypes (EP1-4). In 3D-culture model systems utilizing dog (MDCK) and patient-derived (UCL93, Ox161-C1) kidney cell lines, PGE2 strikingly promoted cystogenesis and inhibited tubulogenesis by stimulating proliferation while reducing apoptosis. The effect of PGE2 on tubulogenesis and cystogenesis in 3D-culture was mimicked or abolished by selective EP2 and EP4 agonists or antagonists but not those specific to EP1 or EP3. In a Pkd1 mouse model (Pkd1fl/fl), kidney PGE2 and COX-2 expression were increased by two-fold at the peak of disease (week four). However, Pkd1fl/fl mice treated with selective EP2 (PF-04418948) or EP4 (ONO-AE3-208) antagonists from birth for three weeks had more severe cystic disease and fibrosis associated with increased cell proliferation and macrophage infiltration. A similar effect was observed for the EP4 antagonist ONO-AE3-208 in a second Pkd1 model (Pax8rta-TetO-Cre-Pkd1fl/f). Thus, despite the positive effects of slowing cyst growth in vitro, the more complex effects of inhibiting EP2 or EP4 in vivo resulted in a worse outcome, possibly related to unexpected pro-inflammatory effects.


KEYWORDS: ADPKD; cyclic AMP; cystogenesis; inflammation; macrophages; prostaglandin E2

Copyright © 2020, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

**Translational Statement**

Autosomal dominant polycystic kidney disease (ADPKD), which currently has limited treatment options, is the major genetic cause of kidney failure in humans. Our study sought to investigate whether selective receptor blockade of prostaglandin E2 action via the EP2 and EP4 receptors, which signal mainly via cyclic adenosine monophosphate, could inhibit cyst formation in experimental disease models. Despite positive effects in cyst assays, an unexpected increase in the cyst burden was observed in 2 Pkd1 mouse models after *in vivo* dosing, associated with an increase in inflammation. Our results do not support the use of EP2 or EP4 antagonists as therapeutic options in ADPKD.

Autosomal dominant polycystic kidney disease (ADPKD) is the most common kidney genetic disorder, accounting for 7%–10% of patients with end-stage renal disease, and is caused by mutations in 1 of 2 genes, PKD1 (~85%) and PKD2 (~15%).1 It is characterized by the formation of fluid-filled cysts that arise from tubular epithelial cells that exhibit a hyperproliferative and pro-apoptotic phenotype.2,3 Recently, the vasopressin V2 receptor (VPV2R) antagonist tolvaptan has been approved for treatment of ADPKD patients who show evidence of rapid disease progression.4,5 However, the use of tolvaptan is associated with poorly tolerated side effects and a rare but unpredictable incidence of liver toxicity.6,7 Hence, the discovery of safer and more effective alternative drugs to slow disease progression in ADPKD is of major clinical interest.

Prostaglandin E2 (PGE2) is a lipid mediator synthesized from arachidonic acid through several enzymatic steps including production of cyclooxygenases (COX-1 and COX-2) and prostaglandin E synthase.8,9 Several studies suggest that COX-2 is the major cyclooxygenase responsible for PGE2 production.7,8 PGE2 binds to 4 different G-protein–coupled receptors (GPCRs)—prostaglandin E2 receptors 1–4 (EP1–4)—which are differentially expressed in different tissues and
signal through different G-proteins, resulting in complex outputs. In particular, EP2 and EP4 are known to couple to Gs, which stimulates cyclic adenosine monophosphate (cAMP) formation by activating adenylyl cyclase. Cyclic AMP is a central player in cyst formation and expansion. Several GPCR ligands (vasopressin V2 receptor [VPV2R], endothelin B, and somatostatin receptors) have been shown to modify disease severity in ADPKD models through modulation of renal cAMP concentrations.

PGE2 has been isolated in cyst fluid, and its urinary concentration has been found to be increased in patients with reduced kidney function. In vitro, the effect of PGE2 on stimulating cyst formation has been shown on inner medullary collecting duct (IMCD)-3 and human epithelial cells. These early observations suggested that PGE2 could be a major modifier of cyst growth. However, the study of PGE2 signalling has been hampered by the lack of potent and selective receptor modulators (agonists and antagonists). Conversely, the more recent availability of these compounds has led to a resurgence of preclinical and clinical investigation of different EP subtypes as selective targets to treat a variety of orphan diseases.

In this article, we report the effects of modifying PGE2 signalling on cyst growth by utilizing new potent and selective receptor modulators of all 4 EP receptors (EP1–4) in cellular and animal models of ADPKD. Our results suggest a striking effect of EP2 and EP4 agonists in inhibiting tubulogenesis and promoting cyst formation and expansion in vitro. However, the administration of EP2 and EP4 antagonists to a neonatal model of ADPKD, the hypomorphic Pkd1-neolox mouse (Pkd1fl/fl), and a postnatal Cre-inducible Pkd1 model (Pax8rtTA-TetO-Cre-Pkd1fl/fl), led, surprisingly, to more severe cystic disease. These results suggest a more complex effect of EP2 and EP4 antagonists in vivo, resulting in a worse outcome in this model, possibly related to unexpected proinflammatory effects.

RESULTS
EP2 and EP4 receptor activation inhibits tubulogenesis and promotes cystogenesis
To study the effect of PGE2 on spontaneous tubulogenesis, the normal human renal epithelial cell line UCL93 was grown in a Type I collagen matrix. After 20 days, prominent tubule structures had formed with evidence of branching (Figure 1a). The addition of different concentrations of PGE2 (1–100 nM) after 6 days of culture significantly increased the percentage of cystic structures, with a 2-fold increase at 10 nM PGE2 (Figure 1b). All 4 EP receptor subtypes are expressed in this line, although EP2 and EP4 were more highly expressed than EP1 and EP3 (data not shown). The effect of PGE2 was mimicked by an EP2 selective agonist (ONO-AE1-259-01) and by an EP4 selective agonist (ONO-AE1-329), suggesting that stimulation of either receptor can initiate cyst formation (Figure 1c and d). Stimulation of UCL93 with PGE2, EP2, or EP4 selective agonists stimulated cAMP formation (Figure 1e and f), suggesting that cyst formation is cAMP-mediated and involves EP2 and EP4.

PGE2 stimulates cyst growth in Madin-Darby canine kidney cell (MDCK) and OX161-C1 cell lines
The potential effect of PGE2 and its receptors on cyst growth was next studied in 3D-cyst assays using the established MDCK II, and in a human PKD1 cystic epithelial cell line, OX161-C1 (Figure 2a). The latter expresses all 4 EP subtypes in a pattern similar to that of UCL93 (data not shown). The addition of PGE2 significantly enhanced cyst growth in both cell lines over time in a dose-dependent manner, with OX161-C1 cells being more sensitive than MDCK II cells to the effect of PGE2 (Figure 2b and c). Given that MDCK II cysts responded in a clearer dosage-dependent manner than OX161-C1, we investigated the effects of PGE2 on proliferation (antigen Ki-67) or apoptotic (cleaved caspase-3) rates in MDCK II cysts. PGE2 had a dual effect on MDCK II cysts, both increasing cell proliferation and inhibiting apoptosis in a dose-dependent manner (Figure 2d–g). We did not measure apoptosis at earlier time points and it is possible that luminal apoptotic cells could have been removed. These changes were significantly correlated to changes in the average cyst area measured in the same wells (Supplementary Figure S1A and B). As expected, PGE2 stimulated cAMP accumulation in both cell lines (Supplementary Figure S1C and D).

EP2 and EP4 agonists mimic PGE2-induced cyst growth
A differential array of EP gene expression revealed fold-changes of 1.55 (EP1), 5.05 (EP2), 1.19 (EP3), and 1.89 (EP4) between PKD1 cystic and normal cells, although only EP2 was significantly increased. We confirmed that OX161-C1 expresses all 4 EP receptor subtypes, and MDCK II expresses EP2 and EP4 mRNA by polymerase chain reaction (data not shown). We next tested the effects of selective agonists to EP1–4 in both cell lines grown in 3D-culture for up to 20 days. The EP1 agonist ONO-DI-004 and the EP3 agonist ONO-AE-248 did not significantly increase cyst area in either MDCK II or OX161-C1 after 14 days of incubation, although a decrease was noted at the highest concentration of ONO-AE-248 in OX161-C1 (data not shown). By contrast, cyst growth in both lines was significantly enhanced by either EP2 (ONO-AE1-259-01) or EP4 (ONO-AE1-329) agonists in a dose-dependent manner (Figure 3a–d). Similar to PGE2, the EP2 and EP4 agonists also enhanced cAMP formation in OX161-C1 and MDCK II (Figure 3e and f) and stimulated MDCKII cyst growth by increasing cell proliferation and decreasing cell apoptosis (Supplementary Figure S2). These results strongly suggest that PGE2 stimulates cyst growth in vitro by activating EP2 and EP4.

EP2 and EP4 antagonists abolish PGE2-induced cyst growth
To confirm that PGE2-induced cyst growth is mediated by EP2 and EP4, we tested the effect of selective EP2 and EP4 antagonists on PGE2-induced cyst growth in both cell lines. As shown in Figure 4, the EP2 antagonist ONO-AE8-111 and the EP4 antagonist ONO-AE8-11 both decreased the effect of PGE2 on cyst growth. Similar effects were observed with the EP2 antagonist PF-04418948 and a different EP4 antagonist.
Taken together, these results confirm that PGE2 induces cyst growth via EP2 and EP4 and that blockade of either receptor is sufficient to inhibit the effect of PGE2.

The PGE2 pathway is upregulated in an early-onset Pkd1 mouse model
To study the regulation of the PGE2 pathway in an in vivo ADPKD model, we utilized the early-onset hypomorphic Pkd1<sup>nl/nl</sup> mouse model. In this model, Pkd1<sup>nl/nl</sup> kidneys were already cystic and larger at birth compared to Pkd1<sup>wt/wt</sup>-wildtype (Pkd1<sup>wt/wt</sup>) at each time point (Supplementary Figure S3A–E). Typically, peak kidney growth and cyst expansion occurred around week 3, followed by a gradual decrease up to week 10 (Figure 5a and b; Supplementary Figure S3F). Cysts developed from multiple nephron segments (distal and proximal tubules, collecting ducts, and loop of Henle) during this growth phase (data not shown). At 3 weeks, Pkd1<sup>nl/nl</sup> kidneys were...
Figure 2 | Prostaglandin E2 (PGE₂) induces cyst growth by increasing proliferation and decreasing apoptosis. (a–c) PGE₂ stimulates cyst growth in Madin-Darby canine kidney cell (MDCK) II and OX161-C1 cells in a dose- and time-dependent manner. Bar = 50 μm. Values are expressed as mean ± SEM; n = 30–78 cysts per condition for MDCK II, and n = 84–113 cysts per condition for OX161-C1. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, compared with the control group. Statistical significance was determined using a 2-way analysis of variance followed by Tukey’s multiple-comparison test. PGE₂ (d,e) stimulates cell proliferation and (f,g) inhibits apoptosis in a dose-dependent manner in MDCK II cysts. The proliferative rate at day 10 was quantified as the percentage of antigen Ki-67–positive cells per cyst. The apoptotic rate was quantified as the percentage of cysts with >5 cleaved caspase-3–positive nuclei. Values are expressed as mean ± SEM, n = 30 cysts per condition. *P < 0.05; **P < 0.01; ****P < 0.0001, compared with the control group. Statistical significance was determined using a 1-way analysis of variance followed by Dunnett’s multiple-comparison test. DAPI, 4',6-diamidino-2-phenylindole. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
Figure 3 | Prostaglandin E receptor (EP)2 and EP4 activation induce cyst growth of Madin-Darby canine kidney cell (MDCK) II and OX161-C1 cells. The (a) EP2 receptor agonist ONO-AE1-259-01 and (b) the EP4 receptor agonist ONO-AE1-329 stimulated cyst growth in (continued)
characterized by an increase in both proliferative (Ki-67–positive) and apoptotic (dUTP nick-end labeling [TUNEL]–positive) cells (Supplementary Figure S4), an accumulation of F4/80-positive cells, and fibrotic tissue especially around cysts (Supplementary Figure S5). Renal cAMP concentrations increased significantly from week 2 to 3 in Pkd1nl/nl kidneys but then decreased sharply after week 4, changing in parallel to fractional total kidney weights (Figure 5a and c).

We next analyzed different components of the PGE2 system in this model. Levels of Ptg2 mRNA (encoding for COX-2) were increased in Pkd1nl/nl kidneys from weeks 2 to 6, followed by a decline up to week 10 (Figure 5d). In 4-week-old animals, PGE2 concentrations in whole kidney lysates was

Figure 4 | Prostaglandin E receptor (EP)2 and EP4 antagonists abolish prostaglandin E2 (PGE2)-induced cyst growth in vitro. The effect of PGE2 (10 nM) on cyst growth in (a,b) Madin-Darby canine kidney (MDCK) II and (c,d) OX161-C1 cells is blocked by EP2 (ONO-AE8-111) or EP4 (ONO-AE3-208) selective antagonists after 14 days and 10 days, respectively. Values are expressed as mean ± SEM, n = 64–75 cysts per condition for MDCK II, and n = 101–144 cysts per condition for OX161-C1. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, compared with the PGE2 group (●). Statistical significance was determined using the nonparametric Kruskal-Wallis test followed by a Dunn’s multiple-comparisons test.

Figure 3 | (continued) MDCK II and OX161-C1 cells. Values are expressed as mean ± SEM, n = 45–72 cysts per condition for MDCK II, and n = 73–162 cysts per condition for OX161-C1. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, compared with the control group. Statistical significance was determined using a 2-way analysis of variance followed by Tukey’s multiple-comparison test. (c) Example of MDCKII cysts after 20 days of ONO-AE1-259-01 or ONO-AE1-329. Bar = 100 μm. (d) Example of OX161-C1 cysts after 10, 14, and 20 days of incubation with ONO-AE1-259-01 or ONO-AE1-329 stimulate cyclic adenosine monophosphate (cAMP) accumulation in (e) MDCK II and (f) OX161-C1 cells after 60 minutes. Values are expressed as mean ± SEM, n = 6. *P < 0.05; **P < 0.01, compared with the control group. Statistical significance was determined using a 1-way analysis of variance followed by Dunnett’s multiple-comparison test or an unpaired t test. DMSO, dimethylsulfoxide.
increased by at least 2-fold: 537 pg/mg protein (Pkd1wt/wt) versus 1174 pg/mg protein (Pkd1nl/nl; Figure 5e). The expression profile of the different PGE2 receptors showed distinct expression patterns over time (Supplementary Figure S6). Ptgser1 and Ptgser4 mRNA were significantly upregulated in Pkd1nl/nl kidney from weeks 4 to 10, with a peak at week 6, whereas Ptgser2 was significantly upregulated at week 2 and also from weeks 6 to 10. Ptgser3 expression was lower in Pkd1nl/nl kidneys between weeks 2 to 6, although this change was not statistically significant. In 2-week-old Pkd1wt/wt kidneys, EP4 was strongly expressed by distal tubules and the loops of Henle, colocalizing with calbindin and Tamm-Horsfall protein, respectively, in serial sections (Supplementary Figure S7A). In 2-week-old Pkd1nl/nl kidneys, EP4 was detected in small cysts and dilated tubules but was not expressed in larger cysts (Supplementary Figure S7B). Unfortunately, we did not find an EP2 antibody suitable for immunohistochemistry.

EP2 and EP4 receptor blockade increases disease severity in vivo in an early-onset Pkd1 mouse model

Given that cyst formation occurred in utero and was obvious in newborn (postnatal day [PN]11) Pkd1nl/nl mice (Supplementary Figure S3), we decided to commence drug treatment shortly after birth. To achieve this, compounds were initially administered through the drinking water (PN1–7) of lactating mothers and after the first week of life, by daily i.p. injection (PN7–20) to the pups. Four treatment groups each received either dimethylsulfoxide (vehicle), the EP2 antagonist PF-04418948, the EP4 antagonist ONO-AE3-208, or both compounds in combination (Figure 6a). Animals from all 4 groups grew normally and tolerated the compounds with normal increases in body weight (data not shown). Unexpectedly, the average kidney weights and kidney-to-body weight ratio from PN21 mice treated with either EP2 or EP4 antagonists alone did not decrease but rather were higher (Figure 6b–d), with a significant increase for the EP4 antagonist–treated animals. Histologic analysis of kidney sections showed that the cystic index in both the EP2- and EP4-treated groups were significantly higher than those of vehicle-treated animals (Figure 6e and f), with a nonsignificant trend (P = 0.056) toward increased fibrosis (Supplementary Figure S8D). Kidney function was not significantly altered between the groups, nor was there a significant change in total kidney cAMP content or apoptosis (Supplementary Figure S8A–C). However, the percentage of Ki-67–positive cells and F4/80–positive cells was significantly increased in both the EP2 and EP4 groups,
Figure 6 | Administration of prostaglandin E receptor (EP)2 and EP4 antagonists worsened the cystic phenotype of Pkd1nl,nl mice. (a) Outline of the experimental design of the in vivo experiments. (b) Kidney weights of PN21 Pkd1nl,nl mice treated with EP2 or EP4 (continued)
with a significant correlation between the percentage of F4/80-positive cells and the kidney-to-body weight ratio (Figure 6g–i). Compared to vehicle-treated animals, mice treated with EP2 and EP4 antagonists in combination had a less severe phenotype than those treated with either compound alone, associated with a trend toward reduced fibrosis, cell proliferation, and macrophage number. Treated animals did not show any significant change between aquaporin (AQP)1- and AQP2-positive tubules, excluding a differential effect on segment-specific cysts (Supplementary Figure S9).

DISCUSSION

In this study, we present clear evidence that PGE2 promotes cystogenesis in cellular models of ADPKD via the EP2 and EP4 receptors. Given that EP2 and EP4 are known to couple to Gs, which stimulates cAMP formation by activating adenyl cyclase,27,28, this confirms that the pro-cystogenic action of PGE2 occurs via cAMP formation. Using selective receptor agonists, we exclude a major role for EP3, which inhibits cAMP generation via Gi29 and EP1, which activates Gq, leading to intracellular Ca2+ elevation through phospholipase C.30 The effect of PGE2 acting via EP2 and EP4 was particularly striking on inhibiting normal tubulogenesis and promoting cystogenesis in a non-cystic human cell line (UCL93). The action of EP2 and EP4 appeared to be independent and nonredundant in both MDCK and OX161-C1. We did not observe a change in the pattern of EP receptor expression between normal (UCL93) versus PKD1 cystic cells. Our results differ from previous reports suggesting a more restricted role for EP2 and EP4 in mediating the action of PGE2 on cyst formation in primary human cystic cells and murine IMCD-3 cells, respectively.31,32 These differences could reflect cell-type differences in EP expression.

The promising effects observed using EP2 and EP4 antagonists on PGE2-induced cyst growth in vitro were, however, not reproduced in vivo. We chose to study a well-established Pkd1 mouse model (Pkd1nl/nl), which has an early-onset phenotype but whose phenotype has been shown to respond to several therapeutic drugs.31–34 Both PGE2 concentration and Ptg2 expression were increased at the peak of cystic disease (3–4 weeks) in parallel to the increase in renal cAMP concentrations. Given that cyst formation was already significant at birth, we decided to administer EP2 and EP4 antagonists from PN1–21 to cover the peak period of cyst formation. Unexpectedly, blockade of either receptor led to an increase in the severity of disease and was associated with an increase in cell proliferation and macrophage infiltration. Similar results were observed for EP4 blockade in a second Pkd1 model (Pax8fl/fl-TetO-Cre-Pkd1f/f) with postnatal disease onset, although in this model, the effect of EP2 antagonism was neutral. These findings could represent differences relating to the timing of disease onset in both models, i.e., neonatal (hypomorphic) and postnatal (inducible).

The simplest explanation for our findings is that EP2 and EP4 antagonist led to a proinflammatory phenotype in vivo. Indeed, the role of PGE2 in inflammation is complex, as it has been reported to exert both pro- and anti-inflammatory responses, depending on the tissue and

Figure 6 | (continued) antagonists. (c) Gross morphology of Pkd1nl/nl kidneys from mice treated with EP2 or EP4 antagonists. (d) Two kidney-to-body weight ratios (2KW/BW), (e) cystic index, and (f) representative images of periodic acid–Schiff–stained kidney sections from Pkd1nl/nl kidneys from mice treated with EP2 or EP4 antagonists. Percentage of (g) Ki-67–positive cells and (h) F4/80-positive cells in kidney sections from mice treated with EP2 or EP4 antagonists. (i) Correlation between the percentage of F4/80-positive cells and fractional kidney weights. Values are expressed as mean ± SEM (n = 6–7 per group). *P < 0.05; **P < 0.01; ***P < 0.001, compared to vehicle group. Statistical significance was determined using an unpaired t test. Av., average; CI, confidence interval; DMSO, dimethylsulfoxide; LK, left kidney; RK, right kidney. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
Figure 7 | Administration of an prostaglandin E receptor (EP)4 antagonist increased the cystic phenotype of Pkd1fl,fl mice. (a) Outline of experimental strategy. (b) Kidney weight (g), and (c) kidney-to-body weight ratio (2KW/BW) of 30-day-old Pkd1fl,fl mice (continued)
The role of EP4 in kidney inflammation has been investigated more extensively than that of EP2. In the unilateral ureteral obstruction (UUO) model, which is characterized by increases in PGE2, COX-2, EP2, and EP4 mRNA, EP4-null mice developed more interstitial fibrosis and macrophage infiltration compared to wild-type UUO mice.42 Conversely, treating UUO-wild type mice with an EP4 agonist (ONO-4819) reduced interstitial fibrosis and macrophages number.37 A similar effect of a different EP4 agonist (CP-044,519-02) on fibrosis and macrophage infiltration was noted in the subtotal (5/6) nephrectomy model of chronic kidney failure.38 These observations are not restricted to kidney disease models, as EP4-null mice develop greater airway inflammation than their wild-type controls in 3 models of airway inflammation.39 The anti-inflammatory effect of EP4 on macrophages could relate to alternative non-Gs/cAMP pathways such as EP4 receptor-associated protein/β-arrestin signaling in these cells.40

By contrast, the role of EP2 in kidney disease models has not been studied in detail. However, a likely role in the regulation of macrophage maturation has emerged. EP2 expression is upregulated in activated peritoneal macrophages,41 but EP2-null macrophages or macrophages treated with EP2 antagonist exhibit enhanced maturation in vitro; EP2-null mice had higher numbers of mature macrophages circulating and in the peritoneal cavity.42 The removal of this restraint on systemic macrophage maturation could have contributed to increased macrophage recruitment in EP2-treated Pkd1 hypomorphomic mice.

Several recent articles have highlighted the role that macrophages could play in modifying disease severity in other murine models of ADPKD.43,44 Macrophages have been shown to promote cyst growth by both proliferation-dependent and proliferation-independent mechanisms.45,46 Typically, alternatively activated (M2-like) macrophages have been associated with tubular proliferation, whereas proinflammatory (M1-like) macrophages can lead to cyst expansion through tubular injury.47 Conversely, the cystic epithelium can play a direct role in stimulating macrophage infiltration (monocyte chemotactic protein [MCP]-1 secretion) or polarization to M2 phenotypes (L-lactic acid secretion).48 Our results add cystic-derived PGE2 to the emerging epithelial-macrophage axis in ADPKD as both a pro-proliferative and anti-inflammatory mediator. Our in vivo results were more complex than anticipated, owing to the opposing effects of EP2 and EP4 on epithelial proliferation and macrophage infiltration or activation. Of interest, mice treated with EP2 and EP4 antagonists in combination had proliferative rates similar to those of vehicle-treated mice, but they still had more macrophages and a higher cystic index. These results suggest that the direct effects of EP2 and EP4 antagonists in blocking PGE2-stimulated epithelial cell proliferation (that we observed in vitro) were unable to counterbalance the negative effect of increased macrophage infiltration or activation that led to both proliferation and injury. A consistent effect in both models was the increase in F4/80-positive macrophage number (especially M2-like) following EP4 receptor blockade. Our data therefore add to the accumulating evidence that macrophages play a key role in modifying cystogenesis in ADPKD. The complexity of different macrophage subpopulations in healthy and diseased kidney has been reported recently by several groups. Of potential relevance to our findings was the reaccumulation of a “juvenile-like” resident macrophage population (R2b) in pre-cystic kidneys of a cilia mouse mutant (Ift88): R2b macrophages express CD206/Mrc1 and Ym1, classical “M2” markers, and appeared to stimulate cystogenesis in this model.47 The role of PGE2 and particularly EP4 in regulating the accumulation and/or activation of M2 and R2b macrophages in cystic kidneys merits further investigation. It would be interesting to test the ability of EP4 (or EP2) agonists to induce anti-inflammatory effects in this and other PKD models, as has been reported elsewhere.47,48 However, we predict that such a test would likely induce direct proliferative effects on cystic epithelial cells.

Our study has some limitations. We only tested the effects of blocking EP2 and EP4 in the earliest phase of disease (PN1–21) coinciding with the peak of cyst formation. Our results therefore do not exclude a role for EP2 or EP4 in the subsequent stages of disease, such as in the late development of fibrosis in this model. Second, the Pkd1+/− model is an early-onset model with significant cystic disease detectable at birth. We did not test the role of blocking EP2 or EP4 in utero, as this could have interfered with embryonic development. A genetic approach would be necessary to test an earlier role for EP2 or EP4 deficiency in the cystic phenotype.

In conclusion, we have shown that PGE2 induces cyst formation and expansion via activation of EP2 and EP4 receptors through stimulating cell proliferation and decreasing cell apoptosis. Despite the positive effects of EP2 and EP4 antagonists on slowing down cyst growth in vitro, the more complex effects of inhibiting EP2 or EP4 in vivo resulted in a
Figure 8 | Macrophage subtypes in prostaglandin E receptor (EP)4 antagonist–treated mice. Fraction of (a) Nos2-F4/80 and (b) Ym1-F4/80 macrophages from Pkd1nl,nl (left) and Pkd1fl,fl mice (right) in vehicle and EP4 antagonist groups. Values are expressed as (continued)
more severe cystic phenotype in vivo due to unexpected proinflammatory effects (Figure 9).

**METHODS**

**Cell lines**

MDCK II cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (Sigma-Aldrich, Dorset, UK), 50 U/ml penicillin/streptomycin (Lonza, Slough, UK), and 2 mmol/l L-glutamine (Lonza), and maintained at 37 °C in a humidified atmosphere of 5% CO2. The generation of conditionally immortalized human normal (UCL93) and Pkd1 cyst-lining epithelial cells [OX161] has been previously described.24,48 In 3D culture, OX161 cells gave rise to predominant cystic (60%) but also simple tubular structures or complex tubulocystic structures. We recloned this line by single-cell dilution to identify clones with a higher ratio (90%) of cysts in 3D culture and chose clone 1 (C1) for further study. Immortalized human cells were cultured in DMEM (Gibco) supplemented with 5% Nu-Serum (Corning, Wilford, UK), 50 U/ml penicillin/streptomycin (Lonza), and 2 mmol/l L-glutamine (Lonza) and maintained at 33 °C in a humidified atmosphere of 5% CO2.

**Experimental animals and study design**

All animal experiments were performed under the authority of a UK Home Office license. Hypomorphic Pkd1fl/fl harboring an intronic neomycin-cassette in the Pkd1 gene and their Pkd1wt/wt and Pkd1fl/wt littermates were sacrificed at different ages from PN1 to PN70 to study the evolution of the disease (n = 2–11 per group).25 Pax8fl/fl; TetO-Cre-Pkd1f/f mice (Pkd1fl/fl) were induced using doxycycline (DOX) by daily i.p. injections for 3 days (5mg/kg per day, PN13/C14). To study the effect of EP2 and EP4 antagonists on disease progression, Pkd1fl/fl (n = 6–7) and Pkd1fl/fl (n = 8–12) were divided into 4 groups: one vehicle-treated control group; one group treated with 5 mg/kg per day PF-04418948, a selective EP2 antagonist; one group treated with 10 mg/kg per day ONO-AE3-208, a selective EP4 antagonist; and one group treated with 5 mg/kg per day PF-04418948 and 10 mg/kg per day ONOAE3-208 in combination. Pkd1fl/fl mice: from PN1 to PN77, drugs were dissolved in the drinking water and delivered to the pups through the milk, and from PN77 to PN20, drugs were administered by daily i.p. injections. Mice from the vehicle group received daily i.p. injections of dimethylsulfoxide in Kolliphor EL (Sigma-Aldrich). Mice were sacrificed at PN21, corresponding to the peak of the disease. Pkd1fl/fl mice: from PN16 to PN29, drugs were administered by daily i.p. injections. Mice from the vehicle group received daily i.p. injections of dimethylsulfoxide in Kolliphor EL. Mice were sacrificed at PN30, corresponding to the peak of the disease.

Cyclic AMP Enzyme-Linked Immunosorbent Assays (ELISAs)

Kidneys were mechanically homogenized in 0.1 M HCl (Acros Organics, Loughborough, UK) using pre-filled Triple-pure zirconium beads (Benchmark Scientific, St Neots, UK) and a microtube homogenizer (Benchmark Scientific) at 4 °C. After centrifugation at ×10,000 g for 10 minutes, cAMP from the supernatant was quantified using an enzyme immunoassay kit (Enzo, Exeter, UK) following manufacturer instructions without acetylation.

Cyclic AMP extracted from cells was quantified using an in-house ELISA we have developed and validated against the commercial ELISA (Supplementary Figure S8E). After 24 hours of starvation, confluent cells were incubated for 30 minutes with 0.25 mmol/l 3-isobutyl-1-methylxanthine (Sigma-Aldrich) and 5 mg/ml lactalbumin hydrolysate (Sigma-Aldrich) prior to incubation with drugs to be tested (Sigma-Aldrich) for 1 hour. Cells were lysed in 0.1 mol/l HCl, and cAMP was measured as follows. ELISA 96-well enzyme immunoassay/radioimmunoassay plates (Costar, Wilford, UK) were coated overnight with 5 μg/ml Goat Anti-Rabbit IgG Antibody (Millipore, Watford, UK) in phosphate buffered saline. After washing the plate with 0.05% Tween 20 in phosphate buffered saline, pH 7.2–7.4, the plates were blocked with 1% bovine serum albumin (Acros-Organics) in phosphate buffered saline, pH 7.2–7.4 for 1 hour at room temperature, followed by additional washes with washing buffer. Competitive reactions to measure cAMP were done by pipetting into wells the same volume of cAMP lysate, neutralizing reagent (Tris-Base 0.1 mol/l; Sigma-Aldrich), rabbit anti-cAMP Antibody (Genscript, Oxford, UK), and cAMP–horseradish peroxidase (Genscript) and incubating the plate for 2 hours at room temperature on a plate shaker. Known concentrations of cAMP (Sigma-Aldrich) diluted in 0.1 mol/l HCl were used to generate a standard curve covering the concentration range 3 to 729 pmol/ml. After extensive washes, the plate was incubated with 3,3',5,5'-tetramethylbenzidine substrate (Thermo Fisher, Paisley, UK) at room temperature for ~20 minutes after which stop solution (2 M sulfuric acid) was added and the absorbance was measured at 450 nm using an ELISA plate reader. Protein concentration was quantified using a detergent compatible protein assay kit (Bio-Rad, Watford, UK) and used to normalize cAMP concentrations.

See the Supplementary Methods for description of other methods used in this study.

**Statistical analysis**

Data are presented as mean ± SEM. Statistical analyses were performed with GraphPad Prism (San Diego, CA) software. The degree of significance is denoted as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The test performed for statistical analysis is indicated in the graph legend.

---

**Figure 8** (continued) mean ± SEM, n = 4 mice per group with 5 randomly selected regions used for counting. *P < 0.05; ***P < 0.001, compared to vehicle group. Statistical significance was determined using an unpaired t test. (c) Fluorescent labeling of kidney sections from Pkd1fl/fl mice stained with mannose receptor C type 1 (Mrc1; red) and 4',6-diamidino-2-phenylindole (DAPI; gray). The boxed area is expanded in the right image to show the presence of multiple Mrc1-positive macrophages surrounding a medium-sized cyst. (d) Mrc1-positive cells were quantified in Pkd1fl/fl treated with vehicle and EP4 antagonist. (e) Correlation between the percentage of F4/80-positive cells and MRC1-positive cells present in serial sections from the same animals. Values are expressed as mean ± SEM, n = 11–12 mice per group. **P < 0.01, compared to vehicle group. Statistical significance was determined using Welch’s t test. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
In vitro, prostaglandin E2 (PGE2) enhances cyst growth by stimulating epithelial cell (EC) proliferation, decreasing EC apoptosis, and stimulating chloride (Cl\(^{-}\)) secretion through EP2- and EP4-mediated cyclic adenosine monophosphate production. In vivo, EP2 and EP4 antagonists also induce an increase in macrophage number, which itself leads to an increase in EC injury and proliferation, counteracting the direct effects of EP2 and EP4 on cyst epithelia. The graphical illustration was drawn using the images from Servier Medical Art by Les Laboratoires Servier, with slight modifications (https://smart.servier.com/). COX-2, cyclooxygenase-2; MAC, macrophage.

Figure 9 | The likely roles of prostaglandin E receptors (EP)2 and EP4 in autosomal dominant polycystic kidney disease pathogenesis.
DISCLOSURE
ACMO has received research funding from ONO Pharmaceuticals and has consultancy agreements with Sanofi-Genzyme, Mironid, and Galapagos through the institution. All the other authors declared no competing interests.

ACKNOWLEDGMENTS
We thank Tim Skerry, Fiona Wright, Carl Wright, Jessica Willis, Maya Boudiffa, and Monica Neilan for helpful advice or technical assistance and the late David Huso (Baltimore PKD Centre) for the gift of Pax8-Cre-Pkd1fl/fl mice. We gratefully acknowledge the gifts of EP agonists and antagonists from ONO Pharmaceuticals and Pfizer. This project was funded by grants from Kidney Research UK (RP40/2014) and the Sheffield Kidney Research Foundation. FA-A was supported by a PhD studentship from the Libyan government.

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Supplementary Methods.

REFERENCES


